Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Status:
Completed
Trial end date:
2015-10-09
Target enrollment:
Participant gender:
Summary
In this study, we are trying to find out if the combination of these two drugs is effective
in treating Waldenstrom's macroglobulinemia (WM). The combination of these two drugs has not
been studied for patients with relapsed or refractory macroglobulinemia. The U.S. Food and
Drug Administration (FDA) has approved bortezomib for the treatment of multiple myeloma, a
cancer that is closely related to Waldenstrom's macroglobulinemia.